Skip Navigation



NDT Advance Access published online on August 8, 2009

Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfp371
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nemeth, Z.
Right arrow Articles by Hamar, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nemeth, Z.
Right arrow Articles by Hamar, P.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org



Increased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to monotherapies—the effect on podocytes

Zalan Nemeth1,*, Gabor Kokeny1,2*, Maria Godo1, Miklós Mózes1, László Rosivall1, Marie-Luise Gross2, Eberhard Ritz3 and Péter Hamar1

1 Department of Pathophysiology, Semmelweis University, Budapest, Hungary 2 Institute of Pathology 3 Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany

Correspondence and offprint requests to: Péter Hamar; E-mail: hampet{at}net.sote.hu



  Abstract

Background. Blockade of the renin–angiotensin–aldosterone system (RAAS) does not completely prevent progression of renal disease. Mineralocorticoid receptor blockade provides additional renoprotection over ACE-inhibition monotherapy. We examined the mechanisms underlying superior renoprotection in the subtotal nephrectomy (SNX) model.

Methods. Sprague-Dawley rats were randomized into six groups: (1) sham-op, (2) SNX without treatment, (3) SNX + quinapril (Q), (4) SNX + spironolactone (S), (5) SNX + combination therapy (Q+S), (6) SNX + combination hydrochlorothiazide + reserpin + hydralazine (HRH). Albuminuria and blood pressure were monitored, and kidneys were examined by morphometric and molecular methods.

Results. In SNX rats, albumin excretion was significantly higher than in sham-op rats. Blood pressure reduction was not significantly different between the treatment groups. All therapies (S, Q, Q+S and HRH) reduced albuminuria; the values were lowest in animals treated with Q+S. The volume density of glomerular matrix and the number of mesangial cells were significantly increased in SNX and were lowest in SNX treated with Q+S. The number of podocytes was reduced in SNX, but was normalized in SNX treated with Q+S. Glomerular volumes and podocyte volumes were significantly higher in SNX than in sham-op. Both volumes were reduced by all interventions, but almost normalized by treatment with Q+S. Expression of collagen IV, TGF-β1 and desmin was increased after SNX and significantly reduced by treatment with Q and Q+S.

Conclusions. In subtotally nephrectomized rats, mineralocorticoid blockade provided additional renoprotection over and above ACE inhibition. Such benefit was paralleled by major changes in podocyte number and morphology and was not blood pressure dependent.

Keywords: aldosterone; chronic kidney failure; progression of chronic renal failure; renin–angiotensin system


* The first two authors contributed equally to this work.

Received for publication: 9. 2.09
Accepted in revised form: 6. 7.09


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.